Pura Vida Investments’s Acorda Therapeutics ACOR Stock Holding History

Pura Vida Investments’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-292	Closed	-$751K	–	100
2017 Q4	$751K	Buy	+292	New	+$830K	0.31%	62

Other funds holding ACOR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Pura Vida Investments's ACOR Position: Q1 2018 in Review

Pura Vida Investments sold out of Acorda Therapeutics (ACOR) in Q1 2018, closing a stake of 292 shares — an estimated $751K sold.

Pura Vida Investments first reported a position in ACOR in Q4 2017 and held it in 1 quarter. The position peaked at $751K in Q4 2017. 162 funds tracked by Wall St. Rank hold ACOR as of Q1 2018.

Pura Vida Investments reported no remaining Acorda Therapeutics position as of Q1 2018 after selling out during the quarter.
Pura Vida Investments sold 292 Acorda Therapeutics shares in Q1 2018, an estimated $751K.
Pura Vida Investments first reported a position in Acorda Therapeutics in Q4 2017 and held it in 1 quarter.
Pura Vida Investments's Acorda Therapeutics position peaked at $751K in Q4 2017.
162 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2018.

Based on Pura Vida Investments's 13F filing for Q1 2018, filed 14 May 2018.